Business
New ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients
ISHLT Guidelines Recommend Earlier Use of AlloMap Heart Starting 2 Months Post-Transplant Based on Strength of Clinical Studies ISHLT Guidelines Recommend
About this update from Caredx, Inc.
[{"type":"text","content":"\nISHLT Guidelines Recommend Earlier Use of AlloMap Heart Starting 2 Months Post-Transplant Based on Strength of Clinical Studies\n\nISHLT Guidelines Recommend Remote Use of GEP and dd-cfDNA Heart Transplant Surveillance, as in HeartCare, May be Used to Reduce the Need for Biopsies and Hospital Visits\n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication1 of new guidelines by the International Society for Heart and Lung Transplantation (ISHLT) supporting the use of CareDx’s non-invasive molecular surveillance portfolio.\n\nThe new ISHLT guidelines support the use of CareDx’s cardiothoracic portfolio, AlloMap® Heart, AlloSure® Heart, and HeartCare® (AlloMap Heart and AlloSure Heart). Specifically, the guidelines:\n\n\nSupport the earlier use of AlloMap Heart starting at two months to five years post-transplant versus starting at six months based on strength of clinical studies.2-4\n\n\nSupport AlloMap gene-expression profiling (GEP) and donor-derived cell-free DNA (dd-cfDNA) for routine post-transplant monitoring, which is new in the current guidelines and reflects increased adoption of non-invasive molecular testing in clinical practice. This includes dd-cfDNA which is new in the current guidelines.\n\n\nSupport remote use of GEP and dd-cfDNA heart transplant surveillance, as in HeartCare, as it may be used to reduce the need for biopsies and hospital visits, which is new in the current guidelines, and as evidenced during the recent COVID pandemic.\n\n\n“We applaud ISHLT and the sub-committee for their recognition of the value and importance of innovative, non-invasive solutions, such as AlloSure, AlloMap, and HeartCare, in managing post-heart transplant patients,” said Reg Seeto, CEO and President of CareDx. “We are proud to be the leader in this space by delivering meaningful clinical utility data and for the recognition by the global transplant community through broad adoption of these ongoing innovations.”\n\nThe new ISHLT guidelines were discussed during the April ISHLT 2022 meeting and have now been finalized, published and available online in the Journal of Heart and Lung Transplantation [...